OA10134A - Therapeutic compounds derived from the neem tree - Google Patents
Therapeutic compounds derived from the neem tree Download PDFInfo
- Publication number
- OA10134A OA10134A OA60623A OA60623A OA10134A OA 10134 A OA10134 A OA 10134A OA 60623 A OA60623 A OA 60623A OA 60623 A OA60623 A OA 60623A OA 10134 A OA10134 A OA 10134A
- Authority
- OA
- OAPI
- Prior art keywords
- purified
- treatment
- cells
- extract
- need
- Prior art date
Links
- 235000013500 Melia azadirachta Nutrition 0.000 title claims abstract description 42
- 230000001225 therapeutic effect Effects 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 title description 23
- 240000005343 Azadirachta indica Species 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 60
- 244000237986 Melia azadirachta Species 0.000 claims abstract description 41
- 208000015181 infectious disease Diseases 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 16
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 15
- 208000036142 Viral infection Diseases 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 3
- 241000224016 Plasmodium Species 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 7
- 208000037819 metastatic cancer Diseases 0.000 claims 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 abstract description 104
- 206010028980 Neoplasm Diseases 0.000 abstract description 29
- 201000011510 cancer Diseases 0.000 abstract description 28
- 244000045947 parasite Species 0.000 abstract description 23
- 238000000605 extraction Methods 0.000 abstract description 18
- 241000700605 Viruses Species 0.000 abstract description 11
- 230000001568 sexual effect Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 201000004792 malaria Diseases 0.000 abstract description 9
- 230000002458 infectious effect Effects 0.000 abstract description 6
- 210000002889 endothelial cell Anatomy 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 230000000181 anti-adherent effect Effects 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 229940082880 azadirachta indica flower extract Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 241000255925 Diptera Species 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 241000223960 Plasmodium falciparum Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000002832 anti-viral assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 5
- 229960003677 chloroquine Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 208000003747 lymphoid leukemia Diseases 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 201000000239 Phlebotomus fever Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000000944 Soxhlet extraction Methods 0.000 description 4
- 241000710772 Yellow fever virus Species 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229940063774 carbon dioxide 5 % Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 210000003936 merozoite Anatomy 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940051021 yellow-fever virus Drugs 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- 208000009182 Parasitemia Diseases 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003701 histiocyte Anatomy 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- -1 octadecylsilyl Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 201000006845 reticulosarcoma Diseases 0.000 description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 3
- 230000001445 schizonticidal effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241001135555 Sandfly fever Sicilian virus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002018 neem oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001563 schizont Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JMBKXUYCBVKSSY-DOTOQJQBSA-N (4as,10as)-6,7-dihydroxy-1,1,4a-trimethyl-3,4,10,10a-tetrahydro-2h-phenanthren-9-one Chemical compound OC1=C(O)C=C2[C@@]3(C)CCCC(C)(C)[C@@H]3CC(=O)C2=C1 JMBKXUYCBVKSSY-DOTOQJQBSA-N 0.000 description 1
- OIYMSAOAFKGCMV-UHFFFAOYSA-N 7-acetylneotrichilenone Natural products CC(=O)OC1CC2C(C)(C)CC=CC2(C)C3CCC4(C)C(CCC4C13C)c5cocc5 OIYMSAOAFKGCMV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000557821 Azadirachta Species 0.000 description 1
- 241001639790 Berghia Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- HPXDQBYDTJMQHA-UHFFFAOYSA-N Gedunin Natural products CC1CC2C3(C)C=CC(=O)C(C)(C)C3CC(OC(=O)C)C2(C)C45OC4C(=O)OC(C15)c6cocc6 HPXDQBYDTJMQHA-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061201 Helminthic infection Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000603223 Homo sapiens Nischarin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100015375 Mus musculus Gnaz gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038995 Nischarin Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001591024 Samea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000004712 cancer cell adhesion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical class CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000000646 gametocidal effect Effects 0.000 description 1
- YJXDGWUNRYLINJ-BHAPSIHVSA-N gedunin Chemical compound C=1([C@H]2[C@]3(C)CC[C@@H]4[C@@]5(C)C=CC(=O)C(C)(C)[C@@H]5C[C@H]([C@]4([C@]33O[C@@H]3C(=O)O2)C)OC(=O)C)C=COC=1 YJXDGWUNRYLINJ-BHAPSIHVSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002129 infrared reflectance spectroscopy Methods 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- JMBKXUYCBVKSSY-UHFFFAOYSA-N nimbidiol Natural products OC1=C(O)C=C2C3(C)CCCC(C)(C)C3CC(=O)C2=C1 JMBKXUYCBVKSSY-UHFFFAOYSA-N 0.000 description 1
- JZIQWNPPBKFOPT-LSYMHUITSA-N nimbolide Chemical compound C=1([C@@H]2C[C@H]3O[C@H]4[C@](C3=C2C)(C)[C@@H]([C@@]2(C)C(=O)C=C[C@@]3(C)C(=O)O[C@@H]4[C@H]23)CC(=O)OC)C=COC=1 JZIQWNPPBKFOPT-LSYMHUITSA-N 0.000 description 1
- WKFCTWCVHKIFBR-UHFFFAOYSA-N nimbolide Natural products COC(=O)CC1C2(C)C(OC3CC(C(=C23)C)c4occc4)C5OC(=O)C6(C)C=CC(=O)C1(C)C56 WKFCTWCVHKIFBR-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940062097 nitrogen 90 % Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 150000003534 tetranortriterpenoids Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/944,201 US5370873A (en) | 1992-09-11 | 1992-09-11 | Therapeutic compounds derived from the neem tree |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10134A true OA10134A (en) | 1996-12-18 |
Family
ID=25480990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA60623A OA10134A (en) | 1992-09-11 | 1995-03-10 | Therapeutic compounds derived from the neem tree |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5370873A (de) |
| EP (1) | EP0671925A4 (de) |
| JP (1) | JPH08504403A (de) |
| KR (1) | KR950703348A (de) |
| AU (1) | AU4844093A (de) |
| BR (1) | BR9307044A (de) |
| CA (1) | CA2144320A1 (de) |
| OA (1) | OA10134A (de) |
| WO (1) | WO1994017815A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5397571A (en) * | 1993-03-25 | 1995-03-14 | W. R. Grace & Co.-Conn. | Co-extraction of azadirachtin and neem oil |
| US5871749A (en) * | 1993-07-27 | 1999-02-16 | Csl Limited | Therapeutic treatment of H. pylori associated gastroduodenal disease |
| WO1997045349A1 (en) * | 1996-05-24 | 1997-12-04 | Marel Hf. | Handling device |
| IN1997DE01715A (de) * | 1997-06-24 | 2015-07-31 | Council Scient Ind Res | |
| US6545167B1 (en) | 2002-04-04 | 2003-04-08 | Fortune Bio-Tech Limited | Simple and effective manufacturing process for large scale recovery of Nimbin, a Neem seed constituent |
| US6866856B2 (en) * | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| JP2005206566A (ja) * | 2004-01-26 | 2005-08-04 | Iwamoto Shigemi | 制癌予防食品 |
| WO2007137386A1 (en) * | 2006-05-26 | 2007-12-06 | Devarajan Anitha | Compositions and methods for the cure of hiv/aids |
| WO2008004244A1 (en) * | 2006-07-05 | 2008-01-10 | Hafiz Anwarul Aziz | Chemical free fertilizer named as homoeo fertilizer and its process |
| BRPI0701208A2 (pt) * | 2007-03-26 | 2008-11-11 | Wilton Viana | processo de obtenÇço de suplemento alimentar e produto assim obtido |
| BR102013021210B1 (pt) | 2013-01-25 | 2015-12-01 | Fundação Universidade Fed De São Carlos | processo de obtenção de nanopartículas biopoliméricas contendo óleo e extratos de azadirachta indica a. juss (neem), nanopartículas biopoliméricas e micropartículas em pó |
| WO2015035199A1 (en) * | 2013-09-06 | 2015-03-12 | Mayo Foundation For Medical Education And Research | Neem compositions used for the treatment of cancer |
| US11324763B2 (en) * | 2014-03-25 | 2022-05-10 | National University Corporation Kagawa University | Malaria transmission prevention agent having rare sugar as effective component thereof and malarial parasite growth regulating agent |
| EP3586924A1 (de) | 2018-06-26 | 2020-01-01 | Vorderwülbecke, Martin | Neem zur behandlung von rls |
| US11291647B2 (en) | 2018-08-30 | 2022-04-05 | Nisarga Biotech Private Limited | Process for preparation of CO2 extract of Azadirachta indica and herbal compositions thereof for treatment of cancers |
| EP4342482A1 (de) | 2022-09-23 | 2024-03-27 | Laurenz Vorderwülbecke | Neembaumblätterextrakt |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3132656C2 (de) * | 1980-08-19 | 1986-09-04 | Terumo Corp., Tokio/Tokyo | Extrakt aus der Rinde des Nim-Baumes (Melia azadirachta) mit antineoplastischer Wirkung |
| FR2488801B1 (fr) * | 1980-08-19 | 1986-08-14 | Terumo Corp | Extraits a l'eau chaude de l'ecorce du margousier, possedant une activite antineoplastique |
| DE3305047A1 (de) * | 1982-02-19 | 1983-09-22 | Terumo Kabushiki Kaisha trading as Terumo Corp., Tokyo | Polysaccharide, ihre herstellung und diese enthaltende therapeutische zusammensetzungen |
| US5196197A (en) * | 1990-08-29 | 1993-03-23 | National Institute Of Immunology | Reversible fertility control for prevention of pregnancy in females |
-
1992
- 1992-09-11 US US07/944,201 patent/US5370873A/en not_active Expired - Fee Related
-
1993
- 1993-09-08 EP EP93921289A patent/EP0671925A4/de not_active Withdrawn
- 1993-09-08 AU AU48440/93A patent/AU4844093A/en not_active Abandoned
- 1993-09-08 KR KR1019950700960A patent/KR950703348A/ko not_active Withdrawn
- 1993-09-08 CA CA002144320A patent/CA2144320A1/en not_active Abandoned
- 1993-09-08 BR BR9307044A patent/BR9307044A/pt not_active Application Discontinuation
- 1993-09-08 JP JP6511477A patent/JPH08504403A/ja active Pending
- 1993-09-08 WO PCT/US1993/008240 patent/WO1994017815A1/en not_active Ceased
-
1995
- 1995-03-10 OA OA60623A patent/OA10134A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08504403A (ja) | 1996-05-14 |
| BR9307044A (pt) | 1999-06-29 |
| US5370873A (en) | 1994-12-06 |
| CA2144320A1 (en) | 1994-08-18 |
| EP0671925A4 (de) | 1996-02-28 |
| KR950703348A (ko) | 1995-09-20 |
| WO1994017815A1 (en) | 1994-08-18 |
| AU4844093A (en) | 1994-08-29 |
| EP0671925A1 (de) | 1995-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molyneux et al. | Phytochemicals: the good, the bad and the ugly? | |
| OA10134A (en) | Therapeutic compounds derived from the neem tree | |
| Lopes et al. | Flavonoids and lignans from Virola surinamensis twigs and their in vitro activity against Trypanosoma cruzi | |
| EP0987024A2 (de) | Immunosuppressiva | |
| MX2011003940A (es) | Proceso para extraer glucosidos cardiacos y composiciones. | |
| US20080152736A1 (en) | Lipid Fraction of Nigella Sativa L. Seeds | |
| Prince et al. | Effect of Syzigium cumini in plasma antioxidants on alloxan-induced diabetes in rats | |
| AU2021469614A1 (en) | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis | |
| JP2002543140A (ja) | 免疫系の標的刺激へのフィランサスの使用 | |
| KR100516827B1 (ko) | 일산화질소생산억제제 | |
| Bergeron et al. | Screening of plants used by North American Indians for antifungal, bactericidal, larvicidal and molluscicidal activities | |
| Mohsin | Evaluation of Phytochemical and Pharmacological Properties of Cichorium intybus (L) Based on Supercritical Fluid Extract. | |
| Sreepriya et al. | Protective effects of Indigofera tinctoria L. against D-galactosamine and carbon tetrachloride challenge on in situ perfused rat liver | |
| CN109535115A (zh) | 了哥王中总香豆素类物质的提取方法及应用 | |
| Mir et al. | Phytochemical isolation and anti-inflammatory properties of various extracts of Lilium polyphyllum | |
| Garbi et al. | In vitro anti-inflammatory properties of methanolic extract of Hibiscus sabdariffa flowers | |
| Krishnaveni et al. | Hepatoprotective effect of Moringa oleifera in isoniazid induced rats | |
| KR100454087B1 (ko) | 항동맥경화 활성을 나타내는 틸리아닌 | |
| WO1998025639A1 (en) | HYPOGLYCEMIC AGENTS FROM HARUNGANA OR $i(VISMIA SPP.) | |
| JP2005523301A (ja) | Ｂａｒｌｅｒｉａｐｒｉｏｎｉｔｉｓｌｉｎｎからの抽出物を含む製薬組成物、およびその調製方法 | |
| KR100516560B1 (ko) | 혈당강하 및 진통제 조성물 | |
| Okokon et al. | Antimalarial activities of Alchornea laxiflora stembark extract and fractions in Plasmodium berghei-infected mice | |
| CN119818586A (zh) | 龙葵果来源纳米囊泡在制备预防和/或治疗前列腺癌药物中的应用 | |
| KR100247565B1 (ko) | 지모추출물을 유효성분으로 함유하는 면역억제제 | |
| Ross | Laurus nobilis |